3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Melanoma
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Peritoneal Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Pain
1
Monoclonal Gammopathy of Undetermined Significance
1
Magnetic Resonance Imaging
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Limited Stage Small Cell Lung Cancer
1
Kidney Neoplasms
1
Hypothyroidism
1
Hyperphagia
1
Hepatic Encephalopathy
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Goiter
1
Interventions
Carboplatin
339
Cisplatin
238
Paclitaxel
203
Radiotherapy
194
Pemetrexed
187
Docetaxel
169
Gemcitabine
157
pembrolizumab
140
Erlotinib Hydrochloride
107
Etoposide
98
Magnetic Resonance Spectroscopy
92
Bevacizumab
91
Specimen Handling
76
Nivolumab
73
Radiosurgery
71
durvalumab
69
Vinorelbine
54
osimertinib
53
Gefitinib
49
Drug Therapy
49
Irinotecan
42
atezolizumab
41
Topotecan
39
Radiation
39
Biopsy
39
Cyclophosphamide
38
Standard of Care
37
Cetuximab
35
Blood Specimen Collection
33
Taxes
32
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lung Neoplasms
×
Glucose
×
Clear all
NCT04863248
2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2
Terminated
10 enrolled
14 charts